Targeting SUMO Signaling to Wrestle Cancer.

Jessie S Kroonen, Alfred C O Vertegaal

Journal: Trends in cancer 2021;7(6):496-510

PMID: 33353838

Free Full Text on Elsevier Science View on PubMed

Abstract

The small ubiquitin-like modifier (SUMO) signaling cascade is critical for gene expression, genome integrity, and cell cycle progression. In this review, we discuss the important role SUMO may play in cancer and how to target SUMO signaling. Recently developed small molecule inhibitors enable therapeutic targeting of the SUMOylation pathway. Blocking SUMOylation not only leads to reduced cancer cell proliferation but also to an increased antitumor immune response by stimulating interferon (IFN) signaling, indicating that SUMOylation inhibitors have a dual mode of action that can be employed in the fight against cancer. The search for tumor types that can be treated with SUMOylation inhibitors is ongoing. Employing SUMO conjugation inhibitory drugs in the years to come has potential as a new therapeutic strategy.

Address: Department of Cell and Chemical Biology, Leiden University Medical Center, Albinusdreef 2, 2333, ZA, Leiden, The Netherlands.; Department of Cell and Chemical Biology, Leiden University Medical Center, Albinusdreef 2, 2333, ZA, Leiden, The Netherlands. Electronic address: [email protected].

DOI: 10.1016/j.trecan.2020.11.009

Link outs

Free resources

Full Text Sources:

https://linkinghub.elsevier.com/retrieve/pii/S2405...

Medical:

https://medlineplus.gov/cancer.html

Other Literature Sources:

Miscellaneous:

https://assays.cancer.gov/non-CPTAC-4051

MeSH Terms: Antineoplastic Agents, Cell Cycle, Cell Proliferation, Clinical Trials as Topic, Cyclopentanes, Gene Expression Regulation, Neoplastic, Humans, NEDD8 Protein, Neoplasms, Pyrazoles, Pyrimidines, Signal Transduction, Small Ubiquitin-Related Modifier Proteins, Sulfides, Sulfonamides, Sumoylation, Ubiquitin-Activating Enzymes